Metformin could positively impact the well-being of patients with autosomal dominant polycystic kidney disease (ADPKD) if proven effective, wrote authors of a study published in Trials. If metformin demonstrates long-term efficacy, it can become a more affordable and accessible treatment option for patients with ADPKD.1
About the Trial
Trial Name: Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
ClinicalTrials.gov ID: NCT04939935
Sponsor: The University of Queensland
Completion Date (Estimated): May 2027
Globally, ADPKD is the fourth most common reason for dialysis initiation, with an estimated prevalence of 1 in 1000 in the general population. Symptoms consist of exponential cyst growth that damages and distorts normal kidney tissue, resulting in enlarged, painful kidneys and can eventually culminate into progressive chronic kidney disease (CKD). Approximately 35.5 million adults live with CKD, and an estimated 1 in 7 US individuals have the disease. Progression of the disease can lead to end-stage renal disease (ESRD) and kidney failure. Patients with CKD can benefit from specialized care from a nephrologist and additional education, and pharmacists are crucial in leading medication management, patient education, and collaboration in the treatment of CKD.1,2
There is a significant need for new condition-specific therapies to slow the rate of cyst growth and the progression of kidney function decline to improve patient outcomes alongside reducing health care spending. Metformin, an oral glucose-lowering agent prescribed to 150 million people globally for type 2 diabetes mellitus (T2DM), has a growing body of preliminary evidence that suggests possible benefits in patients with ADPKD. Investigators conducted an international, prospective, blinded, parallel-group, randomized controlled phase 3 trial, IMPEDE-PKD (NCT04939935), to assess the long-term efficacy and safety of metformin extended release when slowing the rate of kidney function decline, reducing morbidity and mortality, and improving quality of life in patients with ADPKD.1,3
For this trial, 1174 adult patients ages 18 to 70 years with an estimated glomerular filtration rate (eGFR) between 38 and 90 mL/min/1.73 m2 were enrolled. Patients were randomly assigned to receive either extended-release metformin (500–2000 mg per day depending on patient’s level of tolerance and eGFR) or placebo, both of which are administered alongside standard of care over a 2-year duration. The primary end point is the change in eGFR, and secondary end points including severity of change in eGFR, annualized slope of eGFR, composite outcome, kidney failure, ADPKD-related pain, and changes in urine albumin to creatinine ratio, among others.1,3